HUMATROPE is a recombinant DNA polypeptide hormone. HUMATROPE has 191 amino acid residues and a molecular weight of approximately 22 125 daltons. The amino acid sequence of the product is identical to that of the human growth hormone of pituitary origin.
HUMATROPE is synthesized in an Escherichia coli strain modified by the addition of the human growth hormone gene. The biological effects of HUMATROPE are equivalent to those of human growth hormone of pituitary origin.
HUMATROPE is a lyophilized, sterile, white powder for subcutaneous or intramuscular administration after reconstitution.
HUMATROPE is a highly purified preparation and is available in cartons containing 24 mg (72 IU) of somatropin and, when reconstituted with the diluent, provided that the cartridge contains 8.46 mg / mL of somatropin, respectively. Each cartridge also contains the following inactive ingredients: mannitol, glycine and dibasic sodium phosphate and is supplied with a diluent. The diluent contains water for injections, meta-cresol and glycerol.
Your doctor will advise you on your dosage and administration schedule. Do not change your dosage without talking to your doctor.
Usually, treatment with Humatrope is a long term treatment; your doctor may need to adjust your dose over time depending on your body weight and response to treatment. In general, the dose is calculated according to the following recommendations and administered once daily:
Children and adolescents with:
- Growth hormone deficiency:
0.025–0.035 mg/kg body weight daily,
- Turner syndrome:
0.045–0.050 mg/kg body weight daily,
- Chronic problems with the way the kidneys work:
0.045–0.050 mg/kg body weight daily,
- Small for gestational age at birth:
0.035 mg/kg body weight daily. Treatment should be discontinued after the first year of
treatment if the growth rate is insufficient,
- SHOX gene deficiency:
0.045-0.050 mg/kg body weight daily.
Growth hormone deficiency in adults:
Treatment should be started with a low dose of 0.15–0.30 mg daily. Lower starting doses may be required in older and overweight patients. The starting dose may be increased gradually according to your individual requirements. Total daily dose usually does not exceed 1 mg.
Dose requirements may decline with increasing age. Women, especially those on oral oestrogen replacement, may require higher doses than men.
In bodybuilders and athletes the use of growth hormone for bodybuilding, and to improve performance, involves a dose between 2 and 4 IU per day.
At this dose, the user enjoys the benefits of this product in terms of fat loss, recovery and rejuvenation.
The administration of Humatrope, in order to obtain a gain in lean muscle mass, implies a higher dosage, is between 6 to 8 IU daily. A higher dose may increase the side effects. Because of the long duration of action of this compound, a duration of 8 to 12 weeks is desirable, knowing that a duration of 16 weeks is even better.
If you use more Humatrope than you should
If you have injected more Humatrope than you should have, please ask your doctor for advice.
- If you have injected too much Humatrope, initially your blood sugar may decrease and become too low (hypoglycaemia) and subsequently increase and become too high (hyperglycaemia).
- If you inject too much Humatrope over a longer period (years), you may experience overgrowth of some parts of your body such as ears, nose, jaw, hands and feet (acromegaly).
HUMATROPE can cause possible side effects include: aches head, muscle or joint pain (in the hips or knees), swelling associated with tingling in the
hands, weakness, hypertension (rarely), shortness of breath
If you stop using Humatrope
Please ask your doctor for advice before stopping treatment. Interruption or early stopping of treatment with Humatrope may impair the success of the Humatrope treatment